Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort

BACKGROUND: Cabazitaxel is a treatment of metastatic castration-resistant prostate cancer (mCRPC) after docetaxel failure. The FUJI cohort aimed to confirm the real-life overall and progression-free survival (OS, PFS) and safety of cabazitaxel. METHODS: Multicentre, non-interventional cohort of Fren...

Descripción completa

Detalles Bibliográficos
Autores principales: Rouyer, Magali, Oudard, Stéphane, Joly, Florence, Fizazi, Karim, Tubach, Florence, Jove, Jérémy, Lacueille, Clémentine, Lamarque, Stéphanie, Guiard, Estelle, Balestra, Aurélie, Droz-Perroteau, Cécile, Fourrier-Reglat, Annie, Moore, Nicholas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964680/
https://www.ncbi.nlm.nih.gov/pubmed/31719685
http://dx.doi.org/10.1038/s41416-019-0611-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964680/
https://www.ncbi.nlm.nih.gov/pubmed/31719685
http://dx.doi.org/10.1038/s41416-019-0611-6

Ejemplares similares